Ultragenyx Pharmaceutical Inc. buy marge
Start price
19.04.17
/
50%
€58.68
Target price
20.07.17
€63.14
Performance (%)
7.76%
End price
20.07.17
€63.23
Summary
This prediction ended on 20.07.17 with a price of €63.23. With a performance of 7.76%, the BUY prediction by marge for Ultragenyx Pharmaceutical Inc. closed with a slight gain. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -1.503% | -1.503% | -40.994% | -59.916% |
| iShares Core DAX® | -2,20 % | 0,67 % | 0,55 % | 51,11 % |
| iShares Nasdaq 100 | -2,63 % | 2,99 % | 34,11 % | 91,99 % |
| iShares Nikkei 225® | -2,02 % | 3,14 % | 53,42 % | 65,85 % |
| iShares S&P 500 | -1,67 % | 2,40 % | 23,22 % | 66,64 % |
Comments by marge for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical m. Tradingchance on positive results for hypophosphatemia drug test
Ultragenyx Pharmaceutical (NASDAQ:RARE) +19.8% AH on news that its burosumab drug to treat x-linked hypophosphatemia, a genetic kidney disorder, met its primary endpoint in a phase 3 study.
RARE says patients treated with the drug showed a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels vs. 8% on placebo.